Diligence memo · auto-generated · as of July 2, 2026
Cel Sci Corp
Cel Sci Corp looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Cel Sci Corp operates in Pharmaceuticals, based in VIENNA.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Cel Sci Corp has raised $2.5M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.5M on 2017-06-22.
Most recent recorded round closed around 2017-06-22.
Valuation (modeled)modeled
Provath models Cel Sci Corp at approximately $57M (range $1.1M–$451M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.95× the median modeled value of Seed Pharmaceuticals companies in 2016–2018 (71 peers) — value vs value, same stage and era. Within the normal band (95% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 4 months.
Last raise 9.0 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.5× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 31% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 46% of those peers.
Closest niche peers: Chase Therapeutics Corp, Acura Pharmaceuticals, Inc, Paragon Biosciences Skyline Capital, LLC, Phoenix PharmaLabs Inc, Saghmos Therapeutics, Inc..
Peoplefiled
14 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.